Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) Shares Outstanding (Weighted Average) (2018 - 2025)

Historic Shares Outstanding (Weighted Average) for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to $21.2 million.

  • Neurogene's Shares Outstanding (Weighted Average) rose 2486.21% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.2 million, marking a year-over-year increase of 2486.21%. This contributed to the annual value of $17.6 million for FY2024, which is 347151.06% up from last year.
  • Per Neurogene's latest filing, its Shares Outstanding (Weighted Average) stood at $21.2 million for Q3 2025, which was up 2486.21% from $21.1 million recorded in Q2 2025.
  • Neurogene's Shares Outstanding (Weighted Average)'s 5-year high stood at $21.2 million during Q3 2025, with a 5-year trough of $433623.0 in Q1 2023.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $12.1 million, with a median of $16.9 million in 2024.
  • In the last 5 years, Neurogene's Shares Outstanding (Weighted Average) soared by 379825.61% in 2024 and then skyrocketed by 2421.09% in 2025.
  • Over the past 3 years, Neurogene's Shares Outstanding (Weighted Average) (Quarter) stood at $491867.0 in 2023, then surged by 3471.51% to $17.6 million in 2024, then rose by 20.5% to $21.2 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $21.2 million for Q3 2025, versus $21.1 million for Q2 2025 and $21.0 million for Q1 2025.